Petit Science Center

CDT’s Mission

The Center for Diagnostics and Therapeutics is an interdisciplinary initiative to realize viable applications of research discoveries.
Read More 

Announcements

Researchers Led By Georgia State Develop Noninvasive Method To Detect Early-Stage Liver Disease

anatomical rendering of human torso's internal organs and skeletal system with liver highlighted A safer and more sensitive contrast dye for MRI tests developed by a team led by Georgia State University researchers may provide the first effective, noninvasive method for detecting and diagnosing early-stage liver diseases, including liver fibrosis.

“It’s a revolutionary change for the field as the first robust detection of the early stage of liver fibrosis,” said Jenny Yang, a Regents’ Professor in Chemistry at Georgia State and the associate director of the university’s Center for Diagnostics and Therapeutics. “This would help doctors monitor treatment before it is irreversible and help pharmaceutical companies to select the right patients for clinical trials or identify subjects for drug discovery.” Read More…


A start-up, founded by CDT’s own Dr. Yang, was awarded a $2 million federal grant to develop improved magnetic resonance imaging (MRI) agents!

A local start-up, life sciences company founded by Dr. Jenny Yang, Regents’ Professor of Biochemistry at Georgia State University, has received a $2 million federal grant to develop improved magnetic resonance imaging (MRI) contrast agents for the early detection of liver cancers and other cancers, such as uveal melanoma or eye cancer, that have metastasized to the liver. Read More…


New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find

ATLANTA—A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therapeutic treatment for an array of illnesses, including cancer, according to the research team.

ProAgio, which is created from a human protein, targets the cell surface receptor integrin αVβ₃ at a novel site that has not been targeted by other scientists. The researchers found ProAgio induces apoptosis, or programmed cell death, of cells that express integrin αVβ₃. This integrin has been a focus for drug development because abnormal expression of αVβ₃ is linked to the development and progression of a number of diseases.

The findings are reported in the journal Nature Communications.

“This integrin pair, αVβ₃, is not expressed in high levels in normal tissue,” said Zhi-Ren Liu, lead author of the study and professor in the Department of Biology at Georgia State. “In most cases, it’s associated with a number of different pathological conditions. Therefore, it constitutes a very good target for multiple disease treatment.” Read more…


Georgia State-Led Study Paves Way for New Therapies in Fight Against Calcium Disorders

ATLANTA—A study led by researchers at Georgia State University provides new insights into the molecular basis of human diseases resulting from mutations in the calcium-sensing receptor (CaSR), a protein found in cell membranes.

Their findings, published Friday (May 27) in the journal Science Advances, may assist in the development of novel receptor-based therapeutics for mutations that lead to certain types of hypocalcemia and neonatal hyperparathyroidism, in addition to Alzheimer’s disease and some cancers. Read More…


First Noninvasive Early Detection Of Liver Cancer Developed By Georgia State Researchers


ATLANTA—Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis.

CDT ResearchersTheir findings were published Wednesday (May 13) in Proceedings of the National Academy of Sciences.

More than 700,000 people are diagnosed with liver cancer each year. It is the leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths annually, according to the American Cancer Society. The rate of liver cancer in the U.S. has sharply increased because of several factors, including chronic alcohol abuse, obesity and insulin resistance.

Read More »


Congratulations

CDT Member, Dr. Suri Iyer has received a new NIH R61 award of approximately $1.35 million for the next three years (2019-2021) for his research project: “Towards point of care HIV detection using repurposed glucose meters”. This is exciting news for Dr. Iyer’s efforts in point of care detection and diagnosis of infectious diseases. Read More >>

Chemistry Ph.D. graduate, Cassandra Miller has received The Anthony Shuker Scientific Poster Award at the 2019 Georgia Bio Innovation Summit. The award was for her submission of “Visualizing Subcellular Ca2+ Dynamics and Microdomains Using Designed Ca2+ Sensors”. Congratulations, Cassie! Click here for the full list of 2019 winners

Dr. Jun Yin’s recent article on “Orthogonal ubiquitin transfer” is hot! Read More »

CDT members Drs. Aimin Liu and Zhiren Liu have just been named Distinguished University Professors of Chemistry and Biology, respectively. This is an honor reserved only for a small percentage of faculty for their extraordinary contributions to research, teaching, and service.

Dr. Jun Yin’s recent work on SUMO has made the back cover of ChemBioChem. Read more »

Dr. Aimin Liu’s study has been featured by the National Science Foundation on their new site, Science360 News. Read more »

Dr. Jenny Yang, CDT Associate Director, has been named a Distinguished University Professor by Georgia State University. Read more »

Contact Us

Andrea Mahone
Phone: 404-413-3593

Mailing Address:
Center for Diagnostics and Therapeutics
Georgia State University
P.O. Box 5090
Atlanta, GA 30303-5090

Phone: 404-413-3593
Fax: 404-413-3580

Andrea Mahone is the Project Coordinator for The Center for Diagnostics and Therapeutics (CDT).